The effect of tamoxifen and its metabolites on platelet function and nitric oxide release

Leslie R. Deak, Vicki Burack, Dave Flockhart, Jane E. Freedman

Research output: Contribution to journalArticle

Abstract

Tamoxifen is used for the prevention and treatment of breast cancer and its use is associated with an increased risk of thrombosis. Thrombus formation can be decreased by nitric oxide (NO), an inhibitor of platelet function. Therefore, the effect of tamoxifen on platelet activity and platelet NO release was determined. Platelets were incubated with tamoxifen (0.1 mM) or the tamoxifen metabolites 4-hydroxy-tomoxifen (4-OH) or N-desmethyl tamoxifen (NDM) followed by incubation with 17βestradiol (0.01 μM) or vehicle control. Incubation with estradiol alone led to modest inhibition of platelet aggregation, and an increase in NO release (P

Original languageEnglish (US)
JournalClinical Pharmacology and Therapeutics
Volume69
Issue number2
StatePublished - 2001
Externally publishedYes

Fingerprint

Tamoxifen
Nitric Oxide
Blood Platelets
Thrombosis
Platelet Aggregation Inhibitors
Platelet Aggregation
Estradiol
Breast Neoplasms

ASJC Scopus subject areas

  • Pharmacology

Cite this

The effect of tamoxifen and its metabolites on platelet function and nitric oxide release. / Deak, Leslie R.; Burack, Vicki; Flockhart, Dave; Freedman, Jane E.

In: Clinical Pharmacology and Therapeutics, Vol. 69, No. 2, 2001.

Research output: Contribution to journalArticle

Deak, Leslie R. ; Burack, Vicki ; Flockhart, Dave ; Freedman, Jane E. / The effect of tamoxifen and its metabolites on platelet function and nitric oxide release. In: Clinical Pharmacology and Therapeutics. 2001 ; Vol. 69, No. 2.
@article{e1c92749837c45c2a522e4631b9e3d9a,
title = "The effect of tamoxifen and its metabolites on platelet function and nitric oxide release",
abstract = "Tamoxifen is used for the prevention and treatment of breast cancer and its use is associated with an increased risk of thrombosis. Thrombus formation can be decreased by nitric oxide (NO), an inhibitor of platelet function. Therefore, the effect of tamoxifen on platelet activity and platelet NO release was determined. Platelets were incubated with tamoxifen (0.1 mM) or the tamoxifen metabolites 4-hydroxy-tomoxifen (4-OH) or N-desmethyl tamoxifen (NDM) followed by incubation with 17βestradiol (0.01 μM) or vehicle control. Incubation with estradiol alone led to modest inhibition of platelet aggregation, and an increase in NO release (P",
author = "Deak, {Leslie R.} and Vicki Burack and Dave Flockhart and Freedman, {Jane E.}",
year = "2001",
language = "English (US)",
volume = "69",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - The effect of tamoxifen and its metabolites on platelet function and nitric oxide release

AU - Deak, Leslie R.

AU - Burack, Vicki

AU - Flockhart, Dave

AU - Freedman, Jane E.

PY - 2001

Y1 - 2001

N2 - Tamoxifen is used for the prevention and treatment of breast cancer and its use is associated with an increased risk of thrombosis. Thrombus formation can be decreased by nitric oxide (NO), an inhibitor of platelet function. Therefore, the effect of tamoxifen on platelet activity and platelet NO release was determined. Platelets were incubated with tamoxifen (0.1 mM) or the tamoxifen metabolites 4-hydroxy-tomoxifen (4-OH) or N-desmethyl tamoxifen (NDM) followed by incubation with 17βestradiol (0.01 μM) or vehicle control. Incubation with estradiol alone led to modest inhibition of platelet aggregation, and an increase in NO release (P

AB - Tamoxifen is used for the prevention and treatment of breast cancer and its use is associated with an increased risk of thrombosis. Thrombus formation can be decreased by nitric oxide (NO), an inhibitor of platelet function. Therefore, the effect of tamoxifen on platelet activity and platelet NO release was determined. Platelets were incubated with tamoxifen (0.1 mM) or the tamoxifen metabolites 4-hydroxy-tomoxifen (4-OH) or N-desmethyl tamoxifen (NDM) followed by incubation with 17βestradiol (0.01 μM) or vehicle control. Incubation with estradiol alone led to modest inhibition of platelet aggregation, and an increase in NO release (P

UR - http://www.scopus.com/inward/record.url?scp=33748954263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748954263&partnerID=8YFLogxK

M3 - Article

VL - 69

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 2

ER -